HealthX Connect Osaka 2026

1 Jul 2026 | Osaka, Japan

Register
Register
Register

TechnoPro Inc.

Company (large) /大企業

www.technopro.com/rd/contract/lineup/ai-ipsc/Kobe, Japan
2 profile visits

About

*RESEARCH SERVICES: AI, Human iPSC-Neuron and the MEA System for Evaluation of Efficacy, Pharmacology and Safety in Drug Discovery

*COLLABORATIVE RESEARCH: Human Disease Models in Vitro with AI and iPSC-Neuron in 3D and planar

We are a biotech offering research services in drug discovery. In particular for our many activities, a research platform is focused on disease function analysis and toxicology of test drugs with human cells in vitro, which is leveraged by human iPSC-neuron, artificial intelligence (AI) and micro electrode array (MEA) to contribute to drug discovery for diseases of central/peripheral nervous system, and other therapeutic areas. The platform can realize to precisely evaluate efficacy, pharmacology and toxicology to support your consistent stage-ups through the discovery process.

www.technopro.com/rd/corporate2021/wp-content/uploads/2023/10/Human-iPSCneuron-and-AI-for-Drug-SafetyDiscovery.pdf

(in JPN) www.technopro.com/rd/contract/lineup/ai-ipsc/

Technologies / 技術

Digital Biomarkers / デジタルバイオマーカーAI・Data analysis / AI・データ分析Pharmacological/Safety evaluation / 薬効・薬理・安全性評価

Business Type / 業種

CRO /開発業務受託

Disease Area/疾患領域

Neurology & Psychiatry/中枢神経、精神疾患Rare diseases / 希少疾患

Business Domain / 分野

Pharmaceuticals / 医薬品

Additional Information

Requested business parter / ご希望のビジネスパートナー 

Pharmaceuticals / 医薬品R&D/研究開発Academia, techtransfer/学術、技術移転Public organisations, Clusters / 公的機関・クラスター等Neurology & Psychiatry/中枢神経、精神疾患Rare diseases / 希少疾患Pharmacological/Safety evaluation / 薬効・薬理・安全性評価

Representatives

Senior Director

TechnoPro Inc.